



BCR/ABL1 ORDERING GUIDE



Learn more at news.mayocliniclabs.com/hematology or scan the code.

BCR/ABL1 ORDERING GUIDE FOR BLOOD AND BONE MARROW*

*Extracted RNA is not an acceptable specimen and will be rejected if received.

	MAYO ID	TEST NAME	APPROPRIATE ORDERING SCENARIO
DIAGNOSIS	BADX	BCR/ABL1, Qualitative, Diagnostic Assay	Qualitative only. Useful screening assay for presence of BCR/ABL1 disease and for identifying the BCR/ABL1 transcript fusion form at time of diagnosis. Detects common transcript fusions (p210, p190) and can also be used for qualitative monitoring of rare fusion types (i.e., fusions that are not p210 or p190). Will NOT provide a quantitative value.
	BCRFX	BCR/ABL1, Reflex, Qual/Quant	Qualitative with reflex to quantitative. Detects common transcript fusions (p210, p190) and other rare fusions. If p210 or p190 fusion form is specifically identified, quantitative testing is performed to provide initial transcript level. Should NOT be used in patients with a previously established diagnosis of BCR/ABL1 p210 or p190 positive disease requiring monitoring on therapy. In this case use specific quantitative PCR tests (Mayo IDs: BCRAB or BA190) as appropriate.
ORDER BASED ON QUALITATIVE RESULTS OBTAINED FROM TESTING ABOVE			
FOLLOW-UP (QUANTITATIVE)	BCRAB	BCR/ABL1, p210, Quant, Monitor	Quantitative assay for monitoring p210 fusion form only. Will not detect other BCR/ABL1 fusion types, including the p190.
	BA190	BCR/ABL1, p190, Quant, Monitor	Quantitative assay for monitoring p190 fusion form only. Will not detect other BCR/ABL1 fusion types, including the p210.
ORDER BASED ON QUALITATIVE RESULTS OBTAINED FROM TESTING ABOVE			
ADDITIONAL TESTING	BAKDM	BCR/ABL1 Mutation, Sequencing	To identify the presence of acquired BCR/ABL1 mutations associated with resistance to tyrosine kinase inhibitor (TKI) therapy. Testing should be considered when quantitative BCR/ABL1 levels are increasing by 0.5 log or more in consecutive samples, or when therapy is not achieving expected response.